A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 [NCT05620823] or INCB 54707-302 [NCT05620836]).
Inclusion Criteria:
Exclusion Criteria:
Fort Gratiot, Michigan 48059, United States
Inssbruck, 06020, Austria
Ostrava - Poruba, 708 52, Czechia
Århus N, 08200, Denmark
Ginowan-shi, 901-2725, Japan
Itabashi-ku, 173-8610, Japan
Kurume-shi, 830-0011, Japan
Shinjuku-ku, 160-0023, Japan